Identifying biomarkers of response to modified FOLFIRINOX regimens using patient derived xenograft mouse models of pancreatic ductal adenocarcinoma by Eldridge, Meagan
 
 
 
 
 
 
IDENTIFYING BIOMARKERS OF RESPONSE TO MODIFIED FOLFIRINOX REGIMENS USING 
PATIENT DERIVED XENOGRAFT MOUSE MODELS OF PANCREATIC DUCTAL 
ADENOCARCINOMA 
 
 
 
 
 
Meagan Marie Davis Eldridge 
 
 
 
 
 
“A thesis submitted to the faculty at the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Master of Science in the Department of 
Pharmacology in the School of Medicine. 
 
 
 
 
 
 
Chapel Hill 
2014 
 
 
 
 
 
        Approved by:  
 
        Jen Jen Yeh 
 
        Lee Graves 
 
        Rob Nicholas 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014  
Meagan Marie Davis Eldridge 
ALL RIGHTS RESERVED 
 
 
 
 
 
 
	   iii 
 
 
 
ABSTRACT 
Meagan Marie Davis Eldridge: Identifying biomarkers of response to modified FOLFIRINOX 
regimens using patient derived xenograft mouse models of pancreatic ductal adenocarcinoma 
(Under the direction of Jen Jen Yeh) 
 
 Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited effective 
therapies. FOLFIRINOX is a chemotherapeutic regimen for patients with metastatic disease that 
provides an unprecedented median overall survival of 11.1 months. However, significant toxicities 
necessitate dose reductions and limit the number of patients eligible for FOLFIRINOX treatment.  
 I used patient derived xenograft (PDX) mouse models of PDAC to assess efficacy of 
modified regimens and determine if intra-tumoral heterogeneity plays a role in response. I also 
used RNA sequencing of PDX tumors to identify potential biomarkers of response. 
 No significant differences in response to standard and modified FOLFIRINOX regimens 
were observed; however, intra-tumoral heterogeneity affected responses of one PDX tumor line 
to modified regimens. Biomarkers associated with differential responses could not be identified by 
RNA sequencing. RNA sequencing data confirmed previously identified PDAC subtypes, classical 
and basal-like.  
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CHAPTER 1 
 
INTRODUCTION 
 
 Pancreatic cancer is the tenth most commonly diagnosed cancer but is the fourth leading 
cause of cancer-related death in the United States (1). The overall 5-year survival rate is 
approximately 5%, with roughly 44,000 newly diagnosed cases of pancreatic cancer in the United 
States each year (2). Ninety percent of pancreatic cancers are pancreatic ductal 
adenocarcinomas (PDAC), which are malignancies of the exocrine compartment of the pancreas. 
The vast majority of patients are diagnosed when the tumor has already involved nearby vessels 
or has metastasized to distant organs, making them ineligible for potentially curative resection (3). 
Additionally, the incidence of pancreatic cancer is expected to increase by 55% in the next twenty 
years, making it the second leading cause of cancer-related death in the United States (2). The 
rising mortality associated with PDAC is not only due to increased prevalence but also a lack of 
effective long-term treatments (2). 
 The nucleoside analog, gemcitabine, is the most commonly prescribed chemotherapeutic 
regimen for PDAC and has been the standard of care since 1997 when it was directly evaluated 
against fluorouracil in patients with advanced PDAC. Gemcitabine, however, is only marginally 
effective, offering a 10% response rate and 7-month median survival (4). Several drugs have 
been used in combination with gemcitabine in an effort to increase effectiveness, but there have 
been few significant increases in survival or quality of life reported for these combination 
regimens (4).  
 FOLFIRINOX is a novel, promising treatment and has been shown to significantly benefit 
patients suffering from PDAC. FOLFIRINOX is named for the four drugs of which it is composed: 
folinic acid (FOL), fluorouracil (F), irinotecan (IRIN), and oxaliplatin (OX) (5). The 3 cytotoxic 
	   2 
components of the regimen, fluorouracil, irinotecan, and oxaliplatin, have different mechanisms of 
action and non-overlapping toxicities (5). Fluorouracil inhibits the enzyme thymidylate synthase, 
which is required for DNA synthesis. Folinic acid potentiates the action of fluorouracil by 
stabilizing the binding of fluorouracil to thymidylate synthase (6). Irinotecan inhibits 
topoisomerase, the enzyme that unwinds DNA for synthesis, and also prolongs the effect of 
oxaliplatin, which induces DNA cross-links (7).  
 In 2011, the efficacy and safety of FOLFIRINOX for patients with metastatic PDAC was 
assessed against gemcitabine in a phase III randomized controlled clinical trial (5). Previous 
phase I and II clinical trials showed significant toxicities associated with the FOLFIRINOX 
regimen (8, 9). Therefore, only patients with good performance status, measured as a 0 or 1 on 
the Eastern Cooperative Oncology Group performance status scale, were enrolled in the phase III 
clinical trial (5).	  Patients with a performance status of 0 or 1 are “fully active, able to carry on all 
pre-disease performance without restriction” or “restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature,” respectively (10).  
 Results of this study indicated a significantly better objective response rate for patients 
that were treated with FOLFIRINOX compared to patients that received gemcitabine (31.6%, 95% 
CI: 24.7–39.1 versus 9.4%, 95% CI: 5.4–14.7; p<0.001), a greater median overall survival (11.1 
months versus 6.8 months, hazard ratio: 0.57; 95% CI: 0.45–0.73; p<0.001), and longer median 
progression-free survival (6.4 months versus 3.3 months, hazard ratio: 0.47; 95% CI: 0.37–0.59; 
p<0.001) (5). Patients in the FOLFIRINOX arm of the study also reported longer time until 
definitive deterioration compared to patients in the gemcitabine arm. Although FOLFIRINOX was 
more effective than gemcitabine, toxicity occurred much more frequently in patients treated with 
FOLFIRINOX compared to patients in the gemcitabine arm. FOLFIRINOX-treated patients 
experienced significantly more neutropenia (p<0.001), febrile neutropenia (p=0.03), 
thrombocytopenia (p=0.04), diarrhea (p<0.001), and sensory neuropathy (p<0.001). Doses also 
had to be decreased in many patients. Median relative dose intensities for oxaliplatin, irinotecan, 
and fluorouracil were 78, 81, and 82% of their full doses, respectively (5). 
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 Although significant toxicities were associated with FOLFIRINOX treatment, this phase III 
clinical trial demonstrated that FOLFIRINOX is a superior chemotherapy regimen compared to 
gemcitabine for patients with metastatic pancreatic cancer and good performance status. Despite 
these findings, the question still remains: how many patients with metastatic pancreatic cancer 
have good performance status and are likely to benefit from FOLFIRINOX?  
 Currently, 50% of patients with pancreatic cancer present with metastatic disease, but 
poor performance status limits the number of patients eligible for FOLFIRINOX treatment (11). 
However, of the patients with metastatic disease and good performance status, roughly 31% 
respond to treatment (5), a huge increase in response rate compared to other treatments. It is 
imperative that we utilize this effective regimen by making it available to a broader patient 
population. In order to expand the number of patients eligible to receive FOLFIRINOX treatment, 
we must minimize the toxicity of the regimen while maintaining its efficacy.  
 Not only must we limit the toxicity of FOLFIRINOX, but we must also identify patients that 
are most likely to respond to modified regimens. Potential biomarkers of response to therapy can 
be assessed by interrogating the transcriptome of tumors (12). Subtypes have been identified for 
several cancers, such as breast, clear cell renal, and bladder cancers, using RNA sequencing 
and microarrays. Importantly, specific therapeutic targets have been identified for different 
subtypes, and various subtypes have been shown to respond differently to therapy (13-16). Use 
of molecular subtyping tools, such as RNA sequencing, is critical to more effectively treat patients 
by implementing personalized medicine practices.  
 For this study, I aimed to determine if modified FOLFIRINOX regimens, containing 20% 
dose reductions in oxaliplatin, irinotecan, or both, are as effective as the human equivalent 
standard regimen in patient-derived xenograft (PDX) mouse models of PDAC. PDX mice are 
established by subcutaneously implanting human PDAC tissue that is obtained during a patient’s 
surgical resection into the flank of an immunodeficient mouse (17-19). I chose to utilize this 
mouse model because PDX mice accurately recapitulate human response rates and tumor 
heterogeneity. Furthermore, these models provide biological replicates of the same tumor yielding 
an invaluable tool for investigating pancreatic cancer therapies (20, 21).  
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I also sought to determine if intra-tumoral heterogeneity affects response to FOLFIRINOX 
regimens by using PDX mice that were implanted with tumors that arose from a single original 
parent donor but were passaged into 3 different cohort donor mice prior to finally being passaged 
into the experimental PDX mice. This study design provided us with 3 cohorts of experimental 
PDX mice that were implanted with tumors from 3 different regions of the original parent tumor. I 
also investigated potential biomarkers of response to FOLFIRINOX regimens using RNA 
sequencing of the original parent and 3 cohort donor tumors. I repeated this study in 2 different 
PDX tumor lines, corresponding to tumors originally obtained from 2 individual patients. Our 
findings suggest that modified FOLFIRINOX regimens are as effective as the Standard 
FOLFIRINOX regimen; however, I observed different responses to FOLFIRINOX regimens 
between PDX mice from different cohorts within the same tumor line. RNA sequencing of PDX 
tumors confirmed PDAC subtypes that were previously identified in our lab using patient and PDX 
microarray data. The continuation of this work may provide a greater understanding of subtype 
differences and intra-tumoral heterogeneity that affects response to FOLFIRINOX regimens, 
thereby enabling the identification of PDAC patients that are most likely to benefit from this 
promising treatment. 
 
METHODS 
 
PDX Tumor Expansions 
The original parent PDX donor 
tumors (Figure 1a) from lines P505 and 
PancT6 were harvested and implanted 
subcutaneously into 3 naïve 
immunodeficient mice each to establish 
the cohort donor tumors (Figure 1b). A 
piece from each original parent tumor 
was also snap frozen. Cohort donor 
	  
Figure 1: Study design. The tumor of an original parent PDX 
mouse (a) was harvested. A piece of tumor from mouse a was 
implanted subcutaneously into each of 3 mice (b). Upon 
reaching max size, the tumors from these mice were harvested 
and subcutaneously implanted into 30 mice each (c). 
Approximately 5 mice from each cohort were assigned to one of 
the 5 treatment groups. 
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tumors were allowed to grow to approximately 2.0 cm in maximal dimension. Upon reaching 
maximum size, each cohort donor tumor was removed and cut into 31 pieces. Each piece of 
tumor was then implanted subcutaneously into a single nude mouse, for a total of 30 
experimental PDX mice per cohort donor tumor (90 experimental mice per PDX tumor line  
(Figure 1c). An additional piece from each cohort donor tumor was also snap frozen.  
 
FOFIRINOX Dosing 
Because PDX tumors from different lines grow at different rates, I utilized growth data for 
each tumor line to determine the appropriate tumor size at which to begin treatment. For the P505 
tumor line, mice were enrolled in the study when their tumors reached a median volume of 239 
mm3 (range, 196–385 mm3). For the PancT6 tumor line, mice were enrolled in the study when 
their tumors reached a median volume of 196 mm3 (range, 144–486 mm3). Tumor sizes were 
determined using caliper measurements. 
Upon reaching appropriate tumor volume, mice were randomly assigned to one of 4 
treatment groups or the placebo group. Treatment regimens were titled as follows: Standard, Low 
OX (oxaliplatin), Low IRI (irinotecan), Low OX/IRI (oxaliplatin and irinotecan) (Table 1). 0.9% 
NaCl was used as the placebo control. Drug dosages for the Standard regimen were identified as 
the maximum tolerated dosages in nude mice, resulting in less than 20% weight loss during a 28-
day treatment course. FOLFIRINOX was administered intravenously by tail vein injection on a 
weekly basis for 28 days. Folinic acid and oxaliplatin were administered first as a combination, 
mice were rested for 30 minutes, then fluorouracil and irinotecan were administered as a second 
combination. Tumor size and mouse weight were recorded twice per week. Tumors were 
harvested 4 hours after the final treatment and snap frozen for storage.  
 
Table 1: Drug dosages for each of the 4 treatment regimens 
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RNA Sequencing 
 
RNA was isolated from snap frozen 
tumors using the AllPrep DNA/RNA Mini Kit 
(Qiagen®, Hilden, Germany) and sent to BGI 
in Hong Kong for library prepration and 
sequencing. Libraries for RNA sequencing 
were constructed using oligo (dT) selection 
methods and consisted of 200 base pair 
fragments. RNA sequencing was performed 
using the Illumina HiSeq sequencing platform. 
Four samples were run per lane, producing 
approximately 60 million, 50 base pair paired-
end reads per sample (BGI Americas, 
Cambridge, MA). 
 RNA sequencing data was aligned to 
human and mouse genomes, hg19 and 
mm10, respectively, using MapSplice. Reads 
were classified as human, mouse, or of 
ambiguous origin using the Xenome algorithm 
(22). Gene expression levels were determined 
using the RSEM annotation (23).  
 Principal component analysis (PCA) 
was performed to determine sources of gene 
expression variability across the 3 cohort 
donor tumors and original parent tumors for 
the P505 and PancT6 lines. Genes that were 
not expressed in any of our PDX tumors were 
eliminated prior to analysis.  
Figure 2: Modified FOLFIRINOX regimens are as 
effective as the standard regimen. A) Mice were 
weighed once a week prior to treatment to ensure no 
weight loss due to toxicity. Data is plotted as the average 
and standard deviation for each regimen. Dotted lines 
represent mice that died during the course of treatment. 
B) P505 and C) PancT6 mice from all 3 cohorts that 
received the same regimen were pooled. Log2 fold 
change in tumor volume at day 28 compared to pre-
treatment tumor volume is shown on the y-axis. Line 
represents median tumor volume log2 fold change. 
Nearly all p-values were calculated using a 2-way 
ANOVA adjusting for donor effects. #Indicates 2-way 
ANOVA between cohorts 1 and 2 only. ϕ indicates t-test 
for cohort donor 1 mice receiving different regimens. * 
indicates p-value < 0.05. 
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RESULTS 
 
Response to Modified FOLFIRNOX Regimens 
The doses of FOLFIRINOX that were administered were not toxic based on mouse 
weight (Figure 2A). Less than 4% of mice died during the course of treatment.  
To determine if modified FOLFIRINOX regimens were as effective as the Standard 
regimen, I calculated the fold change in tumor volume at day 28 for each mouse. Mice from each 
experimental cohort that received the same regimen were combined into one group for statistical 
purposes. To account for any variability that may exist among different cohorts, I performed a 2-
way ANOVA to compare the response of mice treated with modified FOLFIRINOX regimens to 
mice treated with the Standard regimen. Because mice from only two of the P505 cohorts were 
assigned to the Low OX/IRI regimen due to a number of unexpected deaths in cohort 3 prior to 
study enrollment, a 2-way ANOVA comparing only mice from cohorts 1 and 2 was used to 
evaluate response to this regimen (Figure 2B). Similarly, mice from only one PancT6 cohort were 
assigned to the Low OX/IRI regimen, so a t-test was used to assess differences in response of 
mice from this single cohort donor to the Standard and Low OX/IRI regimens (Figure 2C). For 
both the P505 and PancT6 PDX tumor lines, modified regimens were as effective as the 
Standard regimen. Although overall tumor regression did not occur, nearly all FOLFIRINOX 
regimens provided significant tumor growth inhibition compared to placebo for both tumor lines 
(Figure 2B-C). Mice in PancT6 cohort 1 that were treated with the Low OX/IRI regimen did 
demonstrate statistically significant growth inhibition compared to placebo (t-test, p=0.11); 
however, this is thought to be due to limited sample size (Figure 2C).  
 
Effect of Intra-tumoral Heterogeneity on Response to Modified Regimens 
 To determine the role of intra-tumoral heterogeneity in response to modified 
FOLFIRINOX regimens, I evaluated whether mice from different cohorts that were treated with 
the same regimen demonstrate the same response to therapy. For the P505 tumor line, I did not 
observe statistically significant differences in response in mice from different cohorts, although 
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the data suggest that mice in cohorts 2 and 3 demonstrate better overall response to standard 
FOLFIRINOX than mice in cohort 1 (Figure 3A).  
There were statistically significant differences in response to the Low IRI regimen 
between PancT6 cohorts. Mice in cohorts 1 and 3, denoted by circles and triangles, 
demonstrated greater growth inhibition compared to mice in cohort 2, denoted by squares, when 
treated with the Low IRI regimen. While not significant, mice in cohort 3 also demonstrated better 
response than mice in cohort 2 to the Low OX regimen (p=0.06) (Figure 3B).  
 
Differentiating PDAC Subtypes using Principal Component Analysis 
I used RNA sequencing to assess gene expression differences among the 3 cohorts for 
each tumor line that may contribute to variability in response to FOLFIRINOX. Relative 
expression values for approximately 13,000 genes were obtained after removing genes that were 
not expressed in any of the cohort or parent donor samples.  
I performed PCA to identify differential gene expression that may indicate response to 
FOLFIRINOX regimens. Principal component (PC) 1 comprised genes that differentiated the 2 
PDX tumor lines that were used for our study, P505 and PancT6. Genes with high gene weights 
in PC1 were positively correlated with PancT6 samples, meaning these genes were relatively 
	  
Figure 3: Intra-tumoral heterogeneity may affect response to modified FOLFIRINOX regimens. A) P505; B) 
PancT6. Five to six mice from each cohort were assigned to one of the five treatment groups. Response to treatment 
was evaluated by tumor volume log2 fold change at day 28 compared to day 0. Circles, squares, and triangles 
represent cohorts 1, 2, and 3 for each tumor line, respectively. Line represents median tumor volume log2 fold change 
for each group. For most regimens, statistical differences in response between mice from different cohorts were 
assessed by 1-way ANOVA. # indicates p-value was calculated by unpaired t-Test. * indicates p-value < 0.05. 
A B 
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highly expressed in PancT6 tumors. P505 samples were negatively associated with PC1, 
meaning that genes with low gene weights in PC1 were highly expressed by P505 samples.  
Previous work in our lab using microarray data of both patient and PDX tumor samples 
identified two main subtypes of PDAC, classical and basal-like (24). Out of the 100 most highly 
weighted genes in PC1, 19 of them were also present in the basal-like gene list, and only 5 genes 
were also present in the classical gene list. Alternatively, out of the 100 most lowly weighted 
genes in PC1, 47 of them were also present in the classical gene list, and only 2 were present in 
the basal-like gene list.  The basal-like and classical reference gene lists were composed of a 
total of 229 and 367 genes, respectively. I determined that the overlap in these gene lists was 
highly significant (Fisher’s exact test, p-value < 0.0001), indicating that PancT6 and P505 
samples are of the basal-like and classical subtypes, respectively. These data corroborate 
previous findings in our lab demonstrating unique PDAC subtypes (Figure 4).  
 
Identifying Differential Gene 
Expression Among PancT6 
Cohorts 
Based on the PCA 
scatter plot of the first 2 PCs, 
tumors from PancT6 cohort 
donors 1 (PancT6.b1) and 3 
(PancT6.b3), represented by 
circles and triangles in Figure 
3B, were grouped together and 
were spatially distinct from 
cohort donor 2 (PancT6.b2), 
represented by squares in 
Figure 3B (Figure 4). The parent 
tumor (PancT6.a) also grouped 
	  
Figure 4: Principal component analysis differentiates PDAC 
subtypes. RNA sequencing data was used to perform PCA. Genes that 
were not expressed in any of our samples were eliminated prior to PCA. 
Sample P505.a is the original parent donor for the P505 study; P505.b1, 
P505.b2, and P505.b3 represent cohort donors 1, 2, and 3, respectively. 
Sample PancT6.a is the original parent donor for the PancT6 study; 
PancT6.b1, PancT6.b2, and PancT6.b3 represent cohort donors 1, 2, and 
3, respectively. PC1 (x-axis) differentiated between P505 and PancT6 
samples; the gene list for PC1 validated previously identified PDAC 
subtypes, classical and basal-like. PC2 (y-axis) described unknown 
differences between samples of the same tumor line. 
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with cohort donor 2. Because I observed better response to the Low IRI regimen in mice 
expanded from cohort donors 1 and 3, I termed this group the “Low IRI responders.” I termed the 
cohort donor 2 and the parent tumor group the “Parent + Low IRI non-responder.” These two 
groups fell on opposite sides of PC2, so I hypothesized that PC2 may describe differential gene 
expression that impacts response to the Low IRI regimen. I used GATHER (Gene Annotation 
Tool to Help Explain Relationships), a software tool that returns relevant gene ontologies when 
provided a list of genes, to attempt to identify biological functions that are associated with genes 
ranked in PC2 (25). Genes to be included in the query were determined by first ranking genes by 
PC2 gene weight then identifying genes with the highest relative weights (relative gene weight > 
0.0200). I then filtered this gene list to only include genes with positive gene weights in PC1, 
making these genes important for the basal-like subtype (PancT6). This gene list was comprised 
of 65 genes that were relatively highly expressed by only PancT6 samples and also relatively 
highly expressed in the “Parent + Low IRI non-responder” group. Top gene ontologies returned 
by GATHER included epidermis development, ectoderm development, and histogenesis. Bayes 
factors, which quantify the significance of the association of the input gene list with gene 
ontologies, were 9, 8, and 6, respectively. We used a Bayes factor of 6 as a cutoff for significance 
as suggested by the makers of GATHER. All three top gene ontologies were based on the same 
5 genes from my input list, KRT16, KRT17, S100A7, SPRR1A, and SPRR1B. However, none of 
these genes have been previously associated with response to irinotecan or any of the drugs in 
the FOLFIRINOX regimen. Although this finding was significant, the biological and clinical 
significance of these genes in relation to irinotecan response and pancreatic cancer is unclear.  
I also interrogated gene ontologies associated with lowly weighted genes in PC2. Genes 
with relatively low gene weights in PC2 were identified (relative gene weight < -0.0200) and then 
filtered to include only genes with positive gene weights in PC1. This gene list was composed of 
78 genes that were relatively highly expressed by only PancT6 samples and also relatively highly 
expressed by the “Low IRI responder” group. GATHER returned no significantly associated gene 
ontologies for this input list.  
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I further interrogated gene expression differences that may contribute to variable PancT6 
cohort responses to the Low IRI regimen using manual filtering methods of the full gene 
expression dataset. Because the PancT6 original parent tumor (PancT6.a) also grouped with 
cohort donor 2 (PancT6.b2) tumor by PCA, I continued to utilize this grouping for downstream 
analysis. To filter the data set, I performed unpaired, two-tailed t-tests for each gene between our 
“Parent + Non-responder” and “Responders” groups and chose genes with a t-test p-value < 0.05 
(n=1839). Next, I identified the subset of genes with an average expression difference of 50 
RSEM (expression values) or greater between the two groups (n=101). I imported this list of 101 
genes into GATHER. Results of this query determined protein biosynthesis to be the most 
strongly associated gene ontology, involving 18 genes from my input list (Bayes factor, 15). 
These 18 genes involved in protein biosynthesis were more highly expressed in the “Parent + 
Low IRI non-responder” compared to the “Low IRI responders.” These genes are listed in Table 
2. 
Evaluating Growth Rate Among PancT6 Cohorts 
Because protein synthesis was highly 
associated with our final gene list based on manual 
filtering methods, I hypothesized that mice expanded 
from PancT6 experimental cohort donors 1 and 3 (Low 
IRI responders) may exhibit different growth rates than 
mice expanded from experimental cohort donor 2 (Low 
IRI non-responder). I calculated the amount of time in 
weeks that it took for the tumors of the mice that were 
later randomly assigned to the Low IRI regimen to reach 
150 mm3. I then used a one-way ANOVA to compare 
growth rates between PancT6 cohorts. No statistically 
	  
Figure 5: Pre-treatment growth rates for 
PancT6 mice assigned to the Low IRI 
regimen are not significantly different.	  
The time in weeks taken for each tumor to 
reach 150 mm3 from the date of implant 
was calculated. A one-way ANOVA was 
used to determine differences in growth rate 
between cohorts.	  
Table 2: Differentially expressed genes associated with protein biosynthesis 
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significant differences in growth rate were observed between PancT6 cohorts, indicating that 
although there seems to be greater expression of genes involved in protein synthesis in PancT6 
mice in cohort 2 (Low IRI non-responder) compared to mice in cohorts 1 and 3 (Low IRI 
responders), enhanced expression of genes involved in protein synthesis does not appear to 
affect tumor growth rate (Figure 5). 
 
Assessing Differences Between Classical and Basal-like Subtypes 
 I used a two-way ANOVAs to assess whether classical (P505) and basal-like (PancT6) 
subtypes have different overall responses to FOLFIRINOX regimens. No differences in overall 
response to any FOLFIRINOX regimen were observed between subtypes. 
 To determine whether a greater degree of heterogeneity in response to FOLFIRINOX 
regimens exists among the classical (P505) or basal-like (PancT6) subtype, I performed an F-test 
to assess subtype differences in the variances of the log2 tumor volume fold change for mice from 
different cohort donors that were treated with the same regimen. Mice from no single cohort 
donor had a statistically significantly greater variance in log2 tumor volume fold change than mice 
from other cohort donors that were treated with the same regimen. No statistically significant 
differences in variances of responses were observed between the two subtypes for the Standard, 
Low OX, Low IRI, or Placebo regimens.   
I also investigated whether genes were more heterogeneously expressed among 
classical cohorts or basal-like cohorts. To quantify potential differences, I first deleted all genes 
with RSEM values less than 10 for all cohorts to eliminate genes that were very lowly expressed 
in all of our samples. I then performed an F-test to compare the variances of PancT6 and P505 
cohorts. 247 genes were identified as being statistically more variable in the PancT6 cohorts 
compared to the P505 cohorts. 382 genes were identified as being statistically more variable in 
P505 cohorts compared to PancT6 cohorts. These data indicate that P505 tumors are more 
heterogeneous at the gene expression level compared to PancT6 tumors (p<0.0001, binomial 
test).  
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 I also assessed differences in microscopic heterogeneity within a single PDX tumor line. 
As expected, I observed obvious differences in histopathology between the two PDX tumor lines, 
with P505 (classical) cohort donor tumors displaying much more abundant and larger mucin-
producing glands than PancT6 (basal-like). P505 cohort donor tumors appeared to be overall 
very similar in microscopic features; however, PancT6 cohort donor tumors demonstrated visible 
differences in the abundance of mucin-producing glands. PancT6 cohort donors 1 and 3 (Low IRI 
responders) had more abundant mucin-producing glands than cohort donor 2 (Low IRI non-
responder). Heterogeneity among cohort donor tumors suggests intra-tumoral heterogeneity 
within the original parent tumor which may influence response to FOLFIRINOX regimens (Figure 
6).  
 
 
DISCUSSION 
 
 FOLFIRINOX is the most effective treatment for patients with metastatic PDAC and 
provides approximately a 4-month increase in median overall survival compared to the previous 
	  
Figure 6: PancT6 (Basal-like) tumors are more heterogeneous than P505 (Classical) tumors. A piece of each 
cohort donor tumor from both the P505 and PancT6 tumor lines was fixed in paraffin, sectioned, and stained with 
hematoxylin and eosin. All 3 P505 cohort donor tumors demonstrate large and abundant mucin-producing glands. 
PancT6 cohort donors 1 and 3 have more abundant mucin-producing glands (indicated by black-circles) than 
cohort donor 2, suggesting greater intra-tumoral heterogeneity of PancT6 tumors compared to P505 tumors. All 
images shown at 4x magnification. 
	   14 
standard of care, gemcitabine. However, the number of patients that are eligible to take 
FOLFIRINOX is severely limited by the toxicities of this regimen (5). In accordance with the  
necessitated dose reductions in the phase III clinical trial, I assessed the efficacy of FOLFIRINOX 
regimens with 20% dose reductions of two of the most toxic drugs in the regimen, oxaliplatin and 
irinotecan. I determined that regimens containing 20% dose reductions in one or both of these 
drugs were as effective as the Standard regimen, suggesting that the standard dose in patients 
may provoke more drug-induced toxicities with no definitive benefit in the degree of tumor growth 
inhibition.  
Although the drugs that compose the FOLFIRINOX regimen have different mechanisms 
of action, this does not indicate that the drugs act completely independently of each other. 
Therefore, potential synergistic or antagonistic effects of the combination regimen cannot be 
excluded. It is imperative that we continue to evaluate this regimen in order to identify the optimal 
dosages at which to treat patients so that therapeutic effects can be maximized while minimizing 
toxicities. Future studies should assess the efficacies of FOLFIRINOX regimens containing even 
greater dose reductions in oxaliplatin and irinotecan in addition to determining the effects of 
lowering the dose of fluorouracil.  
Response to chemotherapy may be impacted by the molecular heterogeneity of 
pancreatic tumors. To address this, I evaluated the efficacy of FOLFIRINOX regimens in PDX 
mice implanted with tumors from distinct regions of an original parent tumor. PancT6 mice 
implanted with tumors from different cohort donors responded differently to the Low IRI regimen. 
Mice from different P505 cohorts showed no statistically significant differences in response to any 
of the regimens administered; however, mice in cohorts 2 and 3 tended to respond better to the 
Standard regimen than mice in cohort 1.  
The number of mice that were available for enrollment may have limited our ability to 
identify differential responses between cohorts of the same tumor line. This is a difficult issue to 
overcome because cohort donor tumors must be harvested upon reaching maximum size and 
can only be passaged into a fixed number of mice based on tumor size. The process of 
passaging PDX tumors is also time-sensitive since the tumor is harvested and maintained outside 
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the body prior to being implanted into more mice. Furthermore, not all tumors implanted into mice 
grow successfully. Approximately, 20% of tumors passaged into mice do not grow, and/or mice 
get sick and must be harvested. Out of the 30 mice that were passaged per cohort donor, only 20 
to 25 mice were enrolled in our study due to unexpected deaths or lack of tumor growth. These 
deaths can be attributed to causes unassociated with FOLFIRINOX toxicity. One of the four mice 
that died during the course of treatment was from PancT6 cohort 2. Without factoring in the death 
of this mouse, this PancT6 cohort had an unusual number of pre-treatment deaths with 30% of 
mice from this cohort requiring pre-treatment harvest. These data suggest that the health of many 
mice in this cohort was compromised prior to treatment. Another mouse that died after beginning 
treatment had actually been losing weight prior to the start of treatment, and, retrospectively, 
should have been excluded from our study. The other two deaths that occurred during treatment 
are also likely due to underlying causes that were unrelated to toxicity as we discovered post-
completion of this study that the maximum tolerated dose for fluorouracil in this regimen is 100 
mg/kg rather than 50 mg/kg in nude mice. Unexpected deaths also limited our ability to 
adequately assess the efficacy of the Low OX/IRI regimen. Increasing the number of cohort 
donors or adding an additional passage prior to establishing the experimental cohorts (i.e. 
passage each cohort donor into a second round of 3 cohort donors) are methods to address this 
issue.  
I used PCA to assess overall similarities and differences in gene expression in the parent 
and cohort donor tumors. The results of PCA independently validated previous findings in our lab 
that suggest two PDAC subtypes, basal-like and classical, based on microarray data of patient 
and PDX tumor samples. Overall responses to FOLFIRINOX regimens and variances of 
responses of cohort donor tumors were not statistically significantly different between classical 
(P505) and basal-like (PancT6) tumors. Several factors may have influenced these negative 
results. In addition to the limited number of mice enrolled in each cohort for each tumor line, these 
data account for only one basal-like and one classical tumor line. Because our data consists of an 
n of 2, the statistical power of our study is lacking. As more basal-like and classical PDX tumor 
lines are evaluated in the continuation of this study, the differences in FOLFIRINOX response, 
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variability in response, and heterogeneity in gene expression will be elucidated. The seemingly 
homogenous responses between classical and basal-like subtypes to FOLFIRINOX may also be 
due to using a 4-drug combination therapy. Basal-like and classical subtypes may respond 
differently to one or more drugs in the FOLFIRINOX regimen when used as a single agent. 
Simultaneous treatment using all four drugs may have abrogated differential responses that may 
exist for single drugs. Before repeating this study using other PDX tumor lines, each line should 
be thoroughly evaluated for response to single agent cytotoxics (i.e. fluorouracil, oxaliplatin, and 
irinotecan) at various concentrations using a similar study design that incorporates potential 
differences in response due to molecular heterogeneity of the tumor.  
Alternatively, homogenous responses by the basal-like and classical subtypes in this 
study may be due to insufficient dosing of fluorouracil. Following completion of this study, the 
maximum tolerated dose of FOLFIRINOX was re-evaluated. The phase III clinical trial reported a 
31.6% objective response rate, defined by patients who demonstrated either complete or partial 
responses, in the FOLFIRINOX arm. Additionally, 38.6% of patients achieved stable disease with 
FOLFIRINOX treatment (5). Although my study design only included two tumor lines, the 
response data does not appear to reflect the results of the clinical trial, considering that nearly 
70% of patients in the trial had a stable, partial, or complete response. Overall, neither PancT6 
nor P505 tumors responded to the Standard regimen with a stable, partial, or complete response. 
It is possible that I did not observe a similar frequency in tumor response to the clinical trial 
because both of these tumor lines may be resistant to this therapy. However, our data suggest 
that the Standard regimen may be insufficient to yield stable disease or tumor regression. I re-
assessed the maximum tolerated dose of FOLFIRINOX in nude mice and determined that the 
Standard regimen should contain 100 mg/kg fluorouracil instead of the 50 mg/kg that was used 
for the current study. For subsequent studies, the Standard regimen will consist of the higher 
dose of fluorouracil with the original doses of folinic acid, oxaliplatin, and irinotecan.  
In addition to validating the PDAC subtypes, PCA also split our PancT6 samples into 2 
groups based on PC2. These two groups were largely consistent with the responses that we 
observed to the Low IRI regimen. Genes and biological functions that may be responsible for the 
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differentiation between the two groups were interrogated using various statistical methods and 
tools; however, consistent and significantly associated gene ontologies that may influence 
differential responses to Low IRI could not be identified. The number of samples with available 
RNA sequencing data was likely limiting since this data was only available for the parent and 
cohort donor tumors (n=4). Because one versus one or one versus two comparisons are 
statistically underpowered, I attempted to reconcile gene expression differences by also including 
the parent donor in the analysis since it grouped closely with cohort donor 2. This two versus two 
comparison allowed me to filter my gene list down to 101 genes that were most likely responsible 
for gene expression and response differences between PancT6 cohorts. However, the most 
notable gene ontology associated with this list was protein biosynthesis, which mostly involved 
genes important for ribosome production. Considering that expression of genes in protein 
synthesis may contribute to growth and proliferation, I compared the amount of time it took mice 
from each cohort that were later assigned to the Low IRI regimen to reach a pre-treatment tumor 
volume of 150 mm3. No statistically significant difference in growth rate was observed, nullifying 
the hypothesis that protein biosynthesis corresponded to enhanced tumor growth.  
As previously discussed, future studies should use a greater sample size to better parse 
subtle differences in gene expression due to intra-tumoral heterogeneity. This could be achieved 
by including an additional passage of the cohort donor tumors into 3 mice each prior to 
establishing the experimental cohorts. With this new study design, the parent donor, 3 cohort 
donors, and the 9 pre-experimental cohort donors can be sequenced and provide a total of 270 
experimental mice (9 cohorts of 30 mice each). This larger study design will yield a greater 
sample size for the experimental cohorts and may also provide greater depth to answer the 
question of whether intra-tumoral heterogeneity affects response to FOLFIRINOX regimens. 
Currently, whole-exome data for each cohort donor and parent tumor is being analyzed 
and may potentially reveal single nucleotide polymorphisms that might indicate response to 
FOLFIRINOX regimens. As previously mentioned, future studies will use the re-determined doses 
for the Standard regimen, containing an increased dosage of fluorouracil. Increasing the dose of 
fluorouracil in the Standard regimen may be more clinically applicable and potentially better 
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represent patient response data. Future studies will also assess efficacy and identify potential 
biomarkers of regimens with even greater dose reductions in the cytotoxic components of the 
regimen. These studies may set a precedent for the clinical use of equally effective modified 
FOLFIRINOX regimens that contain substantially decreased doses of one or more of the drugs in 
the regimen. These modified regimens will likely limit drug-induced toxicity and, therefore, may be 
available as a treatment option to a broader population of pancreatic cancer patients.  
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